Page 3

Ovid takes another big swing in neuroscience under a new CEO

After multiple setbacks, the company is chasing a CNS target it believes has “revolutionary” potential.

Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief

The move drew skepticism from investors despite multiple recent research setbacks that have left questions about Sanofi’s ability to confront Dupixent’s looming patent expiration.

Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift

The pharma giant’s acquisition of in vivo CAR-T specialist Orna Therapeutics follows similar deals from AbbVie, Gilead, Bristol Myers Squibb and AstraZeneca.

A protein model designed for space could expand pharma’s definition of ‘druggability’

A computational biology company that started in space tech is looking to change how biopharma finds disease targets by modeling how proteins behave.

New FDA guidance that’s a ‘huge deal’ for clinical trials

Why using Bayesian statistics could transform trial design for rare diseases and beyond.

In a tough market, biotechs can be their own worst enemy

Even with sound science, startups can struggle to make their candidates go the distance.

New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond

Emerging tests offer a bridge to pharma aiming to treat neurodegenerative diseases in their earlier stages.

Bayer sets the stage for a pharma comeback

The pharma giant’s drug sales haven’t wowed in recent years. But that could soon change.

Big Pharma CEOs set sights on massive growth in years to come

The CEOs at Johnson & Johnson, Pfizer and Merck have big plans for future revenue even as they face difficult odds in the here and now.

The most valuable up-and-coming GLP-1s

Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.

Why TrumpRx is stumbling before it gets off the ground

Concerns about potential kickbacks, costs and conflicts have triggered calls for oversight.

Investors crave safer, market-ready biotech bets, widening the early-stage funding gap

In these difficult financial times, venture capital dollars favor later-stage biotechs, forcing drugmakers with earlier-stage candidates to find alternative funding routes.

Mirum doubles down on diversified rare disease strategy

With the purchase of biotech Bluejay, Mirum stays focused on building a company with a broad pipeline and portfolio devoted to rare diseases.

AI regulation lags despite entering higher-risk patient care

While more pharma companies launch DTC platforms, states, not the federal government, are providing guardrails to protect patient privacy and safety.

How Big Pharma is navigating a $300 billion patent cliff

Drugmakers like J&J, Merck and AbbVie are making gains by not relying on one single strategy to shore up losses. 

Pharma’s outlook in 2026: Smoother sailing ahead?

After a turbulent year, the industry has a clearer picture of its new landscape and how to navigate the challenges and opportunities ahead. 

Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential

The promising anti-inflammation target could be the next big thing in cardiovascular and other diseases.

Politicization runs deeper than ever at FDA, risking long-term impacts

Wide-ranging shifts at the FDA have set the stage for decisions that drag the agency through the political mud, according to an economist and public policy expert.

Has Novavax cracked the code for survival in the vaccine arena?

The company’s new partnership with Pfizer is worth up to $530 million — and could be just the beginning.

A potential gene therapy for heart failure is an approach decades in the making

Medera’s mid-stage heart failure gene therapy leverages a “master switch” that could widen the aperture of genetic medicine.

Biopharma layoffs surged last year, but 2026 is a chance to turn the page

Companies are adjusting to turbulence in the U.S. market, and more traditional job loss factors will likely be at play in the coming year.

Big Pharma shops Chinese biotechs to stock GLP-1 pipelines

Novo, Regeneron and Pfizer all landed weight loss deals with China-based companies last year.

Top pharma industry conferences in 2026

Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.

Updated Jan. 26, 2026

US drug pricing policies are ‘red lights’ for investors, and China beckons

Pricing policies like most-favored nation and the Inflation Reduction Act, as well as a destabilized FDA, are pushing investors to look outside the U.S.

Cancer R&D is thriving. Here are the areas to watch in 2026.

ADCs, radioligand therapies and multispecifics are leading the way in cancer innovation.